An oncogene believed to be responsible for glioblastoma brain cancer has been identified. AVIL, a gene that normally helps cells to maintain their shape and size, can shift into overdrive, causing cancer cells to form and spread. Blocking the gene's activity completely destroyed glioblastoma cancer cells in mouse models, but did not have any effect on healthy cells. The findings provide potential new treatment avenues for the deadly brain cancer.
Focused ultrasound treatments show promise in the fight against glioblastoma brain cancer. Sonodynamic therapy may also help treat other difficult-to-treat cancers.
Trifluoperazine, a dopamine receptor antagonist commonly prescribed for schizophrenia, used in combination with radiation therapy delays the growth of glioblastoma brain tumors and prolongs survival for brain cancer.
Novel biomarkers for glioblastoma brain cancer have been identified in bodily fluids. The discovery may lead to a new, simple, non-invasive blood test to detect brain cancer in the future.
After a single session of transcranial electrical stimulation (tES), researchers noted a significant reduction in blood flow to brain tumors. However, there were no alterations in blood flow or activity in the rest of the brain. The technique may be helpful in the treatment of brain cancers such as glioblastoma.
Genetics and microenvironment influence the frequency of glioblastoma cells. Researchers provide a new blueprint for glioblastoma, integrating the malignant cell programs, cancer cell plasticity, and modulation by genetic drivers. The findings shed light on why this form of cancer is so hard to treat effectively.